Monte Rosa Therapeutics (MRT) seeks to recruit an experienced, creative and highly talented DMPK and ADME Scientist who is eager will assit in leading the discovery and development effort to grow the drug pipelines, as well as help lead external GxP compliance research efforts. The Scientist will work MRTx colleagues to participate in all stages of DMPK and ADME assessments, from initial compound screening through to IND and NDA regulatory submissions. Working with Research, Bioanalytical and Clinical Science subject matter experts, provides scientific expertise to ensure that clinical candidates with acceptable drug development characteristics are identified and appropriately characterized. Represents Preclinical Development on Research and Development teams and regularly interfaces with internal and external colleagues to ensure timely and accurate dissemination of DMPK and ADME findings
Experience in the design, conduct, and interpretation of in vitro and in vivo ADME and animal PK studies

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN™ discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs.